Vimpat (Epilepsy) - Forecast and Market Analysis to 2022

Date: February 25, 2013
Pages: 51
Price:
US$ 3,495.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V5947667B74EN
Leaflet:

Download PDF Leaflet

Vimpat (Epilepsy) - Forecast and Market Analysis to 2022
GlobalData has released its new PharmaPoint Drug Evaluation report, “Vimpat (Epilepsy) – Forecast and Market Analysis to 2022”. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer’s Dilantin, Abbott’s Depakote, and Novartis’ Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline’s Trobalt/Potiga and Eisai’s Fycompa which both offer first-in-class mechanisms of action.

Vimpat (lacosamide) is an AED developed by UCB that is currently indicated as an adjunctive therapy for partial-onset seizures in individuals over the age of 17. The drug was approved in the EU and the US in 2008, and is available as tablets, syrup, and an injectable solution. Although the precise mechanism by which Vimpat exerts its antiepileptic effects in humans remains to be elucidated, in-vitro studies have indicated that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing (Errington et al., 2008). This MOA is unique from that of other sodium channel-targeting AEDs, such carbamazepine, lamotrigine, and phenytoin, in that lacosamide is the only drug that reduces voltage-gated sodium channel availability by selective enhancement of slow inactivation, but without apparent interaction with fast-inactivation gating, which is a common feature of the other AEDs (Errington et al., 2008). Lacosamide also binds to collapsin response mediator protein-2 (CRMP-2), a phosphoprotein that is mainly expressed in the nervous system and is involved in neuronal differentiation and control of axonal outgrowth. However, the role of CRMP-2 binding in seizure control is unknown.

Scope
  • Overview of Epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Vimpat including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Vimpat for the top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and India
Reasons To Buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Vimpat performance
  • Obtain sales forecast for Vimpat from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and India)
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Related Reports

3 DISEASE OVERVIEW

3.1 Classification of Seizures
3.2 Etiology and Pathophysiology
  3.2.1 Etiology
  3.2.2 Pathophysiology
  3.2.3 Prognosis
  3.2.4 Quality of Life

4 DISEASE MANAGEMENT

4.1 Diagnosis
4.2 Treatment Guidelines
4.3 Clinical Practice

5 COMPETITIVE ASSESSMENT

5.1 Overview
5.2 Strategic Competitor Assessment

6 VIMPAT (LACOSAMIDE)

6.1 Overview
6.2 Therapeutic Role
6.3 Efficacy
6.4 Safety
6.5 SWOT Analysis
6.6 Forecast

7 APPENDIX

7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
  7.4.1 Prevalent Epilepsy Patients
  7.4.2 Percent Drug-Treated Patients
  7.4.3 General Pricing Assumptions
  7.4.4 Individual Drug Assumptions
  7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
  7.7.1 Authors
  7.7.2 Global Head of Healthcare
7.8 About GlobalData
7.9 Contact Us
7.10 Disclaimer

LIST OF TABLES

Table 1: Epilepsy Syndromes by Age at Onset (2009 ILAE Classification)
Table 2: Classification of Seizures
Table 3: Etiology of Epilepsy According to Age
Table 4: Etiology of Partial Seizures
Table 5: Etiology of Generalized Seizures
Table 6: Some of the Genes Involved in Epilepsy
Table 7: Summary of Diagnostic Tools for Epilepsy
Table 8: Treatment Guidelines for Epilepsy
Table 9: AED Options by Seizure Type
Table 10: Top Three AEDs Prescribed for Epilepsy by Market
Table 11: Types of Epilepsy Surgery
Table 12: Leading Treatments for Epilepsy, 2012
Table 13: Product Profile – Vimpat
Table 14: Vimpat SWOT Analysis, 2012
Table 15: Global Sales Forecasts ($m) for Vimpat (lacosamide), 2012–2022
Table 16: Physicians Surveyed, By Country

LIST OF FIGURES

Figure 1: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation
Figure 2: Mechanisms of Action of AEDs at the Synapse
Figure 3: AED Selection Based on Comorbidity

Ask Your Question

Vimpat (Epilepsy) - Forecast and Market Analysis to 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: